Business Context and Reporting Period
This Form 6-K filing by BiondVax Pharmaceuticals Ltd. (not Scinai Immunotherapeutics Ltd.) covers the month of November 2021, with the report signed on December 2, 2021. The filing serves to incorporate by reference the Company's press release dated November 30, 2021, which announced financial results for the third quarter ended September 30, 2021.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It references Exhibit 99.2, which contains the unaudited interim financial statements for the period ending September 30, 2021, but the data itself is not included in this text.
Material Changes
The filing text does not provide specific details regarding material changes versus the prior comparable period. It only indicates that third-quarter 2021 results were announced via a press release.
Guidance, Outlook, and Risks
The provided text does not include management commentary, future guidance, specific risks, contingencies, or unusual items. It strictly functions as a cover document to reference the attached press release and financial statements.
Investor Verification Checklist
- Verify the correct registrant name is BiondVax Pharmaceuticals Ltd., not Scinai Immunotherapeutics Ltd.
- Review Exhibit 99.1 (Press Release dated November 30, 2021) for specific Q3 2021 financial figures.
- Examine Exhibit 99.2 for the full unaudited interim financial statements ending September 30, 2021.
- Confirm the incorporation of this report into Registration Statements Form F-3 (No. 333-240189) and Form S-8 (No. 333-239344).